Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimasertib versus dacarbazine in previously untreated NRAS-mutant advanced cutaneous melanoma
2012-002669-37Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous melanoma (CM) comparing Pimasertib with Dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Aug 2012; status: completed.
02
Drugs
pimasertibdacarbazine
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2012-002669-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002669-37.